Clearside Biomedical, Inc. (CLSD) Forms $9.59 Double Top; Cactus Class A (WHD) Shorts Increased By 77.63%

Cactus Inc Class A (NYSE:WHD) had an increase of 77.63% in short interest. WHD’s SI was 2.16M shares in June as released by FINRA. Its up 77.63% from 1.22M shares previously. With 569,000 avg volume, 4 days are for Cactus Inc Class A (NYSE:WHD)’s short sellers to cover WHD’s short positions. The stock decreased 1.45% or $0.48 during the last trading session, reaching $32.52. About 256,415 shares traded. Cactus, Inc. (NYSE:WHD) has 0.00% since June 12, 2017 and is . It has underperformed by 12.57% the S&P500. Some Historical WHD News: ; 14/05/2018 – CACTUS INC WHD.N : CITIGROUP RAISES TARGET PRICE TO $38 FROM $32; 09/05/2018 – Cactus 1Q EPS 14c; 08/03/2018 CACTUS INC QTRLY REVENUES UP 9.1% TO $104.8 MLN FROM $96.0 MLN IN PRECEDING QUARTER; 09/05/2018 – CACTUS INC – CURRENTLY EXPECTS TOTAL CAPITAL EXPENDITURES FOR 2018 TO RANGE BETWEEN $50 MLN AND $60 MLN; 10/05/2018 – CACTUS INC WHD.N : RBC RAISES TARGET PRICE TO $34 FROM $32; 06/05/2018 – DJ Cactus Inc Class A, Inst Holders, 1Q 2018 (WHD); 14/05/2018 – CACTUS INC WHD.N : SIMMONS RAISES TARGET PRICE TO $35 FROM $30; 02/05/2018 – Ivy Energy Adds Cactus Inc., Exits Weatherford, Cuts RPC; 09/05/2018 – Cactus 1Q Rev $115.1M; 02/04/2018 – Pioneer Select Mid Cap Growth Adds Cactus Inc

Clearside Biomedical, Inc. (CLSD) formed double top with $10.36 target or 8.00% above today’s $9.59 share price. Clearside Biomedical, Inc. (CLSD) has $306.37M valuation. The stock decreased 2.74% or $0.27 during the last trading session, reaching $9.59. About 336,613 shares traded. Clearside Biomedical, Inc. (NASDAQ:CLSD) has risen 77.87% since June 12, 2017 and is uptrending. It has outperformed by 65.30% the S&P500. Some Historical CLSD News: ; 31/05/2018 – Clearside Biomedical Announces Positive Topline Results from Phase 2 Clinical Trial of CLS-TA Used with Eylea in Patients with; 09/05/2018 – CLSD: STAT SIG IMPROVEMENT IN PRIMARY ENDPOINT OF TRIAL; 31/05/2018 – CLEARSIDE BIOMEDICAL INC – PRIMARY AND SECONDARY ENDPOINTS MET IN 6-MONTH TRIAL; 31/05/2018 – Clearside Biomedical Announces Positive Topline Results from Phase 2 Clinical Trial of CLS-TA Used with Eylea in Patients with Diabetic Macular Edema; 07/03/2018 – CLEARSIDE OFFERING PRICES AT $13.00/SHR; 15/05/2018 – Hillhouse Capital Management Exits Clearside Biomedical; 17/05/2018 – Clearside Biomedical Presenting at UBS Conference May 22; 06/03/2018 – CLEARSIDE ENROLLS FIRST PATIENT IN PHASE 3 TOPAZ RVO TRIAL; 31/05/2018 – CLEARSIDE BIOMEDICAL INC – PATIENTS TREATED WITH CLS-TA ACHIEVED COMPARABLE VISION IMPROVEMENT WITH FEWER TREATMENTS; 23/05/2018 – Clearside Biomedical at Non-Deal Roadshow Hosted By Wedbush

Cactus, Inc. designs, manufactures, sells, and rents a range of wellheads and pressure control equipment. The company has market cap of $2.44 billion. The company's principal products include Cactus SafeDrill wellhead systems, frac stacks, zipper manifolds, and production trees. It has a 0.03 P/E ratio. It also provides field services, such as 24-hour service crews to assist with the installation, maintenance, and safe handling of the wellhead and pressure control equipment, as well as repair services for equipment that it sells or rents.

Analysts await Clearside Biomedical, Inc. (NASDAQ:CLSD) to report earnings on August, 8. They expect $-0.57 EPS, down 5.56% or $0.03 from last year’s $-0.54 per share. After $-0.62 actual EPS reported by Clearside Biomedical, Inc. for the previous quarter, Wall Street now forecasts -8.06% EPS growth.

Among 4 analysts covering Clearside Biomedical (NASDAQ:CLSD), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Clearside Biomedical had 5 analyst reports since June 27, 2016 according to SRatingsIntel. Cowen & Co initiated Clearside Biomedical, Inc. (NASDAQ:CLSD) on Monday, June 27 with “Outperform” rating. The stock of Clearside Biomedical, Inc. (NASDAQ:CLSD) earned “Buy” rating by Stifel Nicolaus on Monday, June 27. The company was maintained on Monday, October 24 by Stifel Nicolaus. Needham initiated Clearside Biomedical, Inc. (NASDAQ:CLSD) rating on Tuesday, June 28. Needham has “Buy” rating and $16 target. Wedbush initiated it with “Outperform” rating and $28 target in Monday, June 27 report.

Clearside Biomedical, Inc. (NASDAQ:CLSD) Ratings Chart